Adaptimmune Therapeutics PLC (ADAP)
0.62
-0.02
(-2.61%)
USD |
NASDAQ |
Nov 22, 10:58
Adaptimmune Therapeutics Total Assets (Quarterly): 317.44M for Sept. 30, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 317.44M |
| June 30, 2024 | 321.70M |
| March 31, 2024 | 258.01M |
| December 31, 2023 | 282.62M |
| September 30, 2023 | 296.64M |
| June 30, 2023 | 342.98M |
| March 31, 2023 | 288.08M |
| December 31, 2022 | 328.92M |
| September 30, 2022 | 332.20M |
| June 30, 2022 | 388.27M |
| March 31, 2022 | 419.80M |
| December 31, 2021 | 469.54M |
| September 30, 2021 | 353.53M |
| June 30, 2021 | 389.79M |
| March 31, 2021 | 411.58M |
| December 31, 2020 | 451.14M |
| September 30, 2020 | 479.02M |
| June 30, 2020 | 512.20M |
| March 31, 2020 | 285.24M |
| Date | Value |
|---|---|
| December 31, 2019 | 181.54M |
| September 30, 2019 | 208.25M |
| June 30, 2019 | 239.52M |
| March 31, 2019 | 270.44M |
| December 31, 2018 | 276.74M |
| September 30, 2018 | 309.62M |
| June 30, 2018 | 211.30M |
| March 31, 2018 | 247.07M |
| December 31, 2017 | 281.15M |
| September 30, 2017 | 301.38M |
| June 30, 2017 | 284.28M |
| March 31, 2017 | 265.98M |
| December 31, 2016 | 234.52M |
| September 30, 2016 | 222.64M |
| June 30, 2016 | 239.56M |
| March 31, 2016 | 261.56M |
| September 30, 2015 | 297.31M |
| December 31, 2014 | 137.71M |
| June 30, 2014 | 55.52M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
181.54M
Minimum
Dec 2019
512.20M
Maximum
Jun 2020
355.51M
Average
337.59M
Median
Total Assets (Quarterly) Benchmarks
| Biodexa Pharmaceuticals PLC | 17.67M |
| NuCana PLC | 25.38M |
| Autolus Therapeutics PLC | 827.49M |
| Bicycle Therapeutics PLC | 996.75M |
| TC BioPharm (Holdings) PLC | 9.171M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 237.45M |
| Shareholders Equity (Quarterly) | 79.99M |
| Debt to Equity Ratio | 0.6234 |
| Current Ratio | 3.848 |
| Net Debt Paydown Yield | -4.10% |